LTQ Orbitrap XL ETD mass spectrometer

LTQ Orbitrap XL ETD 质谱仪

• 批准号: 7842121
• 负责人: Haining Zhu
• 金额: $ 90.79万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-10 至 2012-06-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7842121
• 关键词: Advisory Committees; American; Area; Arts; Basic Science; Biological; Biomedical Research; Cardiovascular Diseases; Chemicals; Chromatography; Commit; Core Facility; Diabetes Mellitus; Dissociation; Electron Transport; Electrostatics; Ensure; Equipment; Eye diseases; Financial Support; Funding; Goals; Health; Housing; Hybrids; Institution; Intention; Ions; Kentucky; Laboratories; Lead; Maintenance; Malignant Neoplasms; Manufacturer Name; Mass Spectrum Analysis; Medical center; Medicine; Mission; Modification; Organic solvent product; Peptides; Positioning Attribute; Post-Translational Protein Processing; Productivity; Proteins; Proteomics; Public Health; Recovery; Research; Research Personnel; Research Support; Resolution; Site; Techniques; Technology; Time; Translations; United States; United States National Institutes of Health; Universities; Women' s Health; college; experience; gene discovery; human disease; improved; innovation; instrument; instrumentation; mass analyzer; mass spectrometer; meetings; member; nano; nervous system disorder; novel; operation; programs; public health relevance; research study; virology; wasting

DESCRIPTION (provided by applicant): The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL/ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The LTQ Orbitrap/ETD hybrid mass spectrometer is a combination of a new linear ion trap (LTQ), a novel and high precision electrostatic ion trap (Orbitrap) mass analyzer, and innovative electron transfer dissociation (ETD) technology. In comparison to the existing mass spectrometers for protein and peptide analysis, this hybrid instrument simultaneously provides high sensitivity (attomoles), high spectrum repetition rates, high mass resolution (60,000 HWFM), high mass accuracy (< 5ppm), and complementary fragmentation techniques (both CID and ETD) during a single experiment. The instrumentation reaches a new level of sensitivity and confidence for identifying peptides and proteins. Moreover, the ETD technology provides multiple unique advantages. Particularly it can preserve the post-translation modifications on peptides during fragmentation and allow the identification of exact modification sites. This equipment will provide state-of-the-art capabilities to the Proteomics Core Facility and enhance the ability of the facility to meet an ever-increasing volume and intensity of research support. This equipment is essential to these ongoing research programs and to stimulating and enabling new collaborative research initiatives on protein identification, posttranslational modification characterization, gene discovery, and functional proteomics. Currently, there is no LTQ Orbitrap/ETD mass spectrometer at UK or any universities in the Commonwealth of Kentucky. The purchase of the instrument is critical to the continuing expansion and enhancement of the proteomics research program in human disease and basic research at UK. As described in this application, 19 NIH-funded investigators from 12 different departments have specific needs for this mass spectrometer. The requested instrument will have a major impact on research capabilities at our institution. To ensure the maximal usage and proper maintenance, the instrument will be housed in the Proteomics Core next to the laboratory of the PI. The PI has over 10 years experience in the area of biological mass spectrometry/proteomics. An Advisory Committee with both internal and external members is assembled for overall guidance for the usage of the shared instrument. Financial support for the long term maintenance and operation of the instrument is committed from the University. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility at UK Medical Center will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, including at least one in the University of Kentucky, four at Thermo Fisher Scientific, and one with Eksigent Technologies. Thus this proposal fits the criteria for Recovery Act funding. The manufacturers of the instrumentation (Thermo Fisher Scientific and Eksigent Technologies) are committed to being environmentally responsible. In particular, the splitless nano-HPLC manufactured by Eksigent Technologies uses significantly less organic solvents compared to other split-flow chromatography instruments, thus generating hundreds- to thousands-fold less chemical waste. Moreover, the biomedical research programs that will be enabled and supported by the requested instrumentation will make discoveries leading to better health of Americans. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer. PUBLIC HEALTH RELEVANCE: The Proteomics Core Facility at the University of Kentucky (UK) College of Medicine requests $947,163 to acquire a LTQ Orbitrap XL ETD hybrid mass spectrometer with an Eksigent nano-HPLC. The goal of this application is to provide advanced mass spectrometry capabilities to meet the proteomics needs of 19 highly productive NIH-funded investigators at UK. The research to be supported by this instrument spans a wide spectrum of biological and biomedical research, including cutting-edge programs focused on neurological disorders, cancer, diabetes, cardiovascular disease, virology, eye diseases, and women's health. The addition of this instrument to the Proteomics Core Facility will significantly enhance the productivity and progress of these research programs, thus advancing the NIH mission to improve public health. The funding of this proposal will lead to the hiring and/or retention of more than six full-time positions, meeting the intention of the Recovery Act. The requested instruments are environmentally friendly. In summary, the funding of this application will make the United States and the world healthier, cleaner and safer.

描述（由申请人提供）：肯塔基大学（英国）医学院的蛋白质组学核心设施要求$ 947,163，以获得具有纳米hplc的LTQ Orbitrap XL/ETD混合质谱仪。该应用程序的目的是提供高级质谱能力，以满足英国19位高产NIH资助的研究人员的蛋白质组学需求。 LTQ Orbitrap/ETD杂交质谱仪是新的线性离子陷阱（LTQ）的组合，这是一种新颖且高精度的静电离子陷阱（Orbitrap）质量分析仪，以及创新的电子传递分离（ETD）技术。与现有的蛋白质和肽分析的质谱仪相比，该杂种仪器同时提供高灵敏度（Attomoles），高光谱重复率，高质量分辨率（60,000 HWFM），高质量精度（<5ppm）以及在单个实验过程中的综合片段化技术（<5ppm）和配置的碎裂技术（COIN CORPENTARITY）。该仪器达到了识别肽和蛋白质的新敏感性和信心水平。此外，ETD技术提供了多个独特的优势。特别是它可以在碎裂过程中保留对肽的翻​​译后修改，并允许确定精确的修饰位点。该设备将为蛋白质组学核心设施提供最新的功能，并增强该设施达到不断增加的研究量和研究支持的能力。该设备对于这些正在进行的研究计划至关重要，并刺激和实现有关蛋白质识别，翻译后修饰表征，基因发现和功能蛋白质组学的新的合作研究计划。目前，英国或肯塔基州的任何大学都没有LTQ Orbitrap/ETD质谱仪。购买仪器对于英国人类疾病和基础研究的蛋白质组学研究计划的持续扩展和增强至关重要。如本应用程序中所述，来自12个不同部门的19名NIH资助的研究人员对该质谱仪有特定的需求。要求的工具将对我们机构的研究能力产生重大影响。 为了确保最大使用和适当的维护，该仪器将安置在PI实验室旁边的蛋白质组学核心中。 PI在生物质谱/蛋白质组学领域具有10多年的经验。与内部和外部成员都组装了一个咨询委员会，以用于使用共享工具的总体指导。该工具的长期维护和运作的财务支持是由大学实施的。该仪器支持的研究涵盖了广泛的生物学和生物医学研究，包括着重于神经系统疾病，癌症，糖尿病，心血管疾病，病毒学，眼部疾病和女性健康的尖端计划。在英国医学中心的蛋白质组学核心设施中增加了该工具将显着提高这些研究计划的生产率和进步，从而促进NIH的改善公共卫生任务。 该提案的资金将导致雇用和/或保留六个以上的全职职位，其中包括肯塔基大学的至少一项，其中四个在Thermo Fisher Scientific，其中一项具有Eksigent Technologies。因此，该提案符合恢复法的标准。 仪器的制造商（Thermo Fisher Scientific和Eksigent Technologies）致力于对环境负责。特别是，与其他分流流色谱仪器相比，由Eksigent Technologies生产的无分解的纳米HPLC使用的有机溶剂要少得多，从而产生了数百到数千倍的化学废物。此外，所请求的仪器将启用和支持的生物医学研究计划将使美国人改善健康。总而言之，该申请的资金将使美国和世界更健康，更清洁，更安全。 公共卫生相关性：肯塔基大学（英国）医学院的蛋白质组学核心设施要求$ 947,163购买具有纳米hplc的LTQ Orbitrap XL XL ETD杂种质谱仪。该应用程序的目的是提供高级质谱能力，以满足英国19位高产NIH资助的研究人员的蛋白质组学需求。该仪器支持的研究涵盖了广泛的生物学和生物医学研究，包括着重于神经系统疾病，癌症，糖尿病，心血管疾病，病毒学，眼部疾病和女性健康的尖端计划。将该工具添加到蛋白质组学核心设施中将显着提高这些研究计划的生产率和进步，从而促进NIH改善公共卫生的使命。该提案的资金将导致雇用和/或保留六个以上的全职职位，满足《恢复法》的意图。请求的仪器对环保。总而言之，该申请的资金将使美国和世界更健康，更清洁，更安全。

项目成果

Manganese superoxide dismutase promotes interaction of actin, S100A4 and Talin, and enhances rat gastric tumor cell invasion.

• DOI: 10.3164/jcbn.14-146
• 发表时间: 2015-07
• 期刊: Journal of clinical biochemistry and nutrition
• 影响因子: 2.4
• 作者: Indo HP;Matsui H;Chen J;Zhu H;Hawkins CL;Davies MJ;Yarana C;St Clair DK;Majima HJ
• 通讯作者: Majima HJ